PMN Financials ProMIS Neurosciences Inc.
5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | -$40M | — | — | 3155.8% | -432.6% | — | — | $6M |
| 2024 | — | $3M | — | — | 16.9% | 14.7% | — | — | $13M |
| 2023 | — | -$13M | — | — | -352.0% | -97.0% | — | $0 | $13M |
| 2022 | — | -$18M | — | — | 1340.2% | -260.8% | -$17M | — | $6M |
| 2021 | — | -$10M | — | — | -173.0% | -55.2% | -$9M | $4M | $17M |
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$12M | — | — | -23.7% | -20.7% | — | — | $53M |
| Mar '26 | — | -$8M | — | — | -13.6% | -12.2% | — | — | $64M |
| Dec '25 | — | -$11M | — | — | 848.1% | -116.2% | — | — | $6M |
| Sep '25 | — | -$12M | — | — | -126.0% | -54.0% | — | — | $15M |
| Jun '25 | — | -$10M | — | — | 2644.4% | -106.4% | — | — | $5M |
| Mar '25 | — | -$7M | — | — | -77.6% | -53.8% | — | — | $8M |
| Dec '24 | — | -$238207 | — | — | -1.4% | -1.3% | — | — | $13M |
| Sep '24 | — | $9M | — | — | 127.5% | 37.8% | — | — | $22M |
| Jun '24 | — | -$3M | — | — | 115.2% | -186.1% | — | — | $992463 |
| Mar '24 | — | -$4M | — | — | -4714.8% | -102.4% | — | — | $2M |
| Dec '23 | — | -$4M | — | — | -95.4% | -26.3% | — | $0 | $13M |
| Sep '23 | — | -$2M | — | — | -34.9% | -13.2% | — | — | $17M |
| Jun '23 | — | -$2M | — | — | 27.1% | -154.3% | — | — | $1M |
| Mar '23 | — | -$5M | — | — | 80.3% | -112.0% | — | — | $3M |
| Dec '22 | — | -$7M | — | — | 539.1% | -104.9% | -$5M | — | $6M |
| Sep '22 | — | -$6M | — | — | -816.3% | -110.7% | -$5M | — | $4M |
| Jun '22 | — | -$3M | — | — | -40.9% | -26.9% | -$4M | — | $9M |
| Mar '22 | — | -$2M | — | — | -56.0% | — | -$3M | — | — |
| Dec '21 | — | -$2M | — | — | -39.7% | -12.6% | -$4M | $4M | $17M |
| Sep '21 | — | -$1M | — | — | -15.5% | — | — | — | — |
Valuation over time
How the market has priced PMN against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 3.1× (Dec '24) to 21.8× (Nov '25).
Frequently asked questions
Is PMN growing its revenue and profit?
See the revenue and net-income charts above for ProMIS Neurosciences Inc.'s multi-year trend.
How much debt does PMN have?
As of FY2025, ProMIS Neurosciences Inc. reported — of total debt against $6M of cash.
What is PMN's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
What is PMN's P/E ratio?
As of Sep '26, ProMIS Neurosciences Inc. traded at a price-to-earnings ratio of about 21.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.